Fewer than 10% of patients who could benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it releases its initial recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for broader and more equitable access to GLP-1 medication.
Per forecasts, more than two billion could be living with obesity by 2030 if no action is taken.
"Our new guidelines recognises that excess weight is a chronic disease that can be treated with holistic and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to broad availability to the treatments that can assist patients in reducing substantial weight, notes the body.
GLP-1 Therapy Shortage
Even under the present best projected outlook, the production of these medications might only reach about 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation urges governments and firms to expand access, through strategies like voluntary licensing.
Exclusive production rights on the active ingredient – the main component of a leading brand – is scheduled to end in several countries in 2026.
The Way Obesity Injections Operate
These medications replicate a biological compound to delay gastric emptying, suppress the appetite and increase satiety so individuals reduce food intake.
Patients usually begin shedding pounds after several weeks of beginning the once-weekly jabs.
Studies indicates patients may regain a significant portion within a year of discontinuing the medication, as their typical food cravings resume.
Being above a healthy weight raises your chance for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity impacts people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
